Literature DB >> 23597109

Paradoxical effects of short-term antidepressant treatment in fMRI emotional processing models in volunteers with high neuroticism.

M Di Simplicio1, R Norbury2, A Reinecke2, C J Harmer2.   

Abstract

BACKGROUND: Short-term antidepressant administration has been reported to decrease amygdala response to threat in healthy volunteers and depressed patients. Neuroticism (N) is a risk factor for depression but has also been associated with slow or incomplete remission with antidepressant drug treatment. Our aim was to investigate early selective serotonin reuptake inhibitor (SSRI) administration neural effects on implicit processing of fearful facial expressions in volunteers with high levels of N.
METHOD: Highly neurotic subjects received 20 mg/day citalopram versus placebo for 7 days in a double-blind, between-groups design. On the last day haemoperfusion and functional magnetic resonance imaging (fMRI) data during a gender discrimination task with fearful and happy faces were acquired. A control group of non-neurotic volunteers was also tested.
RESULTS: High-N volunteers had reduced responses to threatening facial expressions across key neural circuits compared to low-N volunteers. SSRI treatment was found to elevate resting perfusion in the right amygdala, increase bilateral amygdalae activation to positive and negative facial expressions and increase activation to fearful versus happy facial expressions in occipital, parietal, temporal and prefrontal cortical areas.
CONCLUSIONS: These results suggest that 7 days of SSRI administration can increase neural markers of fear reactivity in subjects at the high end of the N dimension and may be related to early increases in anxiety and agitation seen early in treatment. Such processes may be involved in the later therapeutic effects through decreased avoidance and increased learning about social 'threat' cues.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23597109     DOI: 10.1017/S0033291713000731

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  13 in total

Review 1.  Identifying predictors, moderators, and mediators of antidepressant response in major depressive disorder: neuroimaging approaches.

Authors:  Mary L Phillips; Henry W Chase; Yvette I Sheline; Amit Etkin; Jorge R C Almeida; Thilo Deckersbach; Madhukar H Trivedi
Journal:  Am J Psychiatry       Date:  2015-02-01       Impact factor: 18.112

2.  A Double-Blind Randomized Trial to Investigate Mechanisms of Antidepressant-Related Dysfunctional Arousal in Depressed or Anxious Youth at Familial Risk for Bipolar Disorder.

Authors:  Duncan C Honeycutt; Melissa P DelBello; Jeffrey R Strawn; Laura B Ramsey; Luis R Patino; Kyle Hinman; Jeffrey Welge; David J Miklowitz; Booil Jo; Thomas J Blom; Kaitlyn M Bruns; Sarah K Hamill Skoch; Nicole Starace; Maxwell J Tallman; Manpreet K Singh
Journal:  J Pers Med       Date:  2022-06-20

Review 3.  A neurocognitive model for understanding treatment action in depression.

Authors:  Matthew B Warren; Abbie Pringle; Catherine J Harmer
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-09-19       Impact factor: 6.237

4.  Negative evaluation bias for positive self-referential information in borderline personality disorder.

Authors:  Dorina Winter; Cornelia Herbert; Katrin Koplin; Christian Schmahl; Martin Bohus; Stefanie Lis
Journal:  PLoS One       Date:  2015-01-22       Impact factor: 3.240

Review 5.  Attention to emotional stimuli in borderline personality disorder - a review of the influence of dissociation, self-reference, and psychotherapeutic interventions.

Authors:  Dorina Winter
Journal:  Borderline Personal Disord Emot Dysregul       Date:  2016-10-04

6.  Exploring the prediction of emotional valence and pharmacologic effect across fMRI studies of antidepressants.

Authors:  Daniel S Barron; Mehraveh Salehi; Michael Browning; Catherine J Harmer; R Todd Constable; Eugene Duff
Journal:  Neuroimage Clin       Date:  2018-08-11       Impact factor: 4.881

7.  'Can you look me in the face?' Short-term SSRI administration reverts avoidant ocular face exploration in subjects at risk for psychopathology.

Authors:  Martina Di Simplicio; Sonia Doallo; Giulia Costoloni; Gustavo Rohenkohl; Anna C Nobre; Catherine J Harmer
Journal:  Neuropsychopharmacology       Date:  2014-07-18       Impact factor: 7.853

8.  Novel Primate Model of Serotonin Transporter Genetic Polymorphisms Associated with Gene Expression, Anxiety and Sensitivity to Antidepressants.

Authors:  Andrea M Santangelo; Mitsuteru Ito; Yoshiro Shiba; Hannah F Clarke; Evelien Hs Schut; Gemma Cockcroft; Anne C Ferguson-Smith; Angela C Roberts
Journal:  Neuropsychopharmacology       Date:  2016-03-21       Impact factor: 7.853

9.  Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder.

Authors:  Azmeraw T Amare; Klaus Oliver Schubert; Fasil Tekola-Ayele; Yi-Hsiang Hsu; Katrin Sangkuhl; Gregory Jenkins; Ryan M Whaley; Poulami Barman; Anthony Batzler; Russ B Altman; Volker Arolt; Jürgen Brockmöller; Chia-Hui Chen; Katharina Domschke; Daniel K Hall-Flavin; Chen-Jee Hong; Ari Illi; Yuan Ji; Olli Kampman; Toshihiko Kinoshita; Esa Leinonen; Ying-Jay Liou; Taisei Mushiroda; Shinpei Nonen; Michelle K Skime; Liewei Wang; Masaki Kato; Yu-Li Liu; Verayuth Praphanphoj; Julia C Stingl; William V Bobo; Shih-Jen Tsai; Michiaki Kubo; Teri E Klein; Richard M Weinshilboum; Joanna M Biernacka; Bernhard T Baune
Journal:  Front Psychiatry       Date:  2018-03-06       Impact factor: 4.157

10.  Polygenic risk scores for major depressive disorder and neuroticism as predictors of antidepressant response: Meta-analysis of three treatment cohorts.

Authors:  Joey Ward; Nicholas Graham; Rona J Strawbridge; Amy Ferguson; Gregory Jenkins; Wenan Chen; Karen Hodgson; Mark Frye; Richard Weinshilboum; Rudolf Uher; Cathryn M Lewis; Joanna Biernacka; Daniel J Smith
Journal:  PLoS One       Date:  2018-09-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.